newsfilter
← Latest News
GlobeNewswire·

Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial

Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine’s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder Vancouver, Canada, July 13, 2026